Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Whole blood transfusion is a blood product intervention being evaluated for the management of coagulopathy in patients with acute traumatic hemorrhage. Unlike standard component therapy, which uses separated red blood cells, plasma, and platelets, whole blood provides all these components in physiologic proportions in a single unit. The specific product used in the T-STORHM trial by the Direction Centrale du Service de Santé des Armées is type O, leukocyte-depleted, and contains low titers of hemolysins to minimize transfusion reactions. This approach aims to simplify logistics in mass casualty scenarios and improve the early availability of clotting factors and platelets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on whole blood (Établissement Français du Sang).